Cre‐dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice
Year: 2016
Type: article
Abstract: DREADDs, designer receptors exclusively activated by designer drugs, are engineered G protein-coupled receptors (GPCR) which can precisely control GPCR signaling pathways (for example, Gq, Gs, and Gi). This chemogenetic technology for control of GPCR signaling has been successfully applied in a variety of in vivo studies, including in mice, to remotely control GPCR signaling, for example, in neurons, glia cells, pancreatic β-cells, or cancer cells. In order to fully explore the in vivo applications of the DREADD technology, we generated hM3Dq and hM4Di strains of mice which allow for Cre recombinase-mediated restricted expression of these pathway-selective DREADDs. With the many Cre driver lines now available, these DREADD lines will be applicable to studying a wide array of research and preclinical questions. genesis 54:439-446, 2016. © 2016 Wiley Periodicals, Inc.
Source: genesis
DOI: 10.1002/dvg.22949
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
Awards: Scalable technologies for illuminating the druggable GPCR-ome, A transgenic platform for highly specific and remote control of neuronal activity, DREADD2.0: AN ENHANCED CHEMOGENETIC TOOLKIT, Elucidating the signal transduction pathways regulating CCK-mediated adult hippocampal neurogenesis, Predoctoral Training in Pharmacological Sciences
OpenAlex ID: W2405001780